Trusted Resources: News & Meetings
Latest announcements and gatherings
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) From Abeona Therapeutics
Ultragenyx Pharmaceutical Inc. and Abeona Therapeutics Inc. announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the terms of the agreement, Ultragenyx will assume responsibility for the ABO-102 program and in return Abeona is eligible to receive tiered royalties of up to 10% on net sales and commercial milestone payments following regulatory approval.
“Based on promising data from Abeona’s clinical program, regulatory feedback to date, and our experience developing treatments for other MPS diseases, we believe ABO-102 has the potential to be a transformative therapy for patients with MPS IIIA,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “Our team’s expertise in MPS and gene therapy clinical development makes this program a seamless integration, and it has the potential to be our first gene therapy to market. The Sanfilippo community has been waiting too long for a first treatment and we believe we can help accelerate this program.”
BookmarkRelated Content
-
Losing Stanley – My Little Boy Doesn’t Recognise Me AnymoreLittle Stanley Barnes was diagnosed with...
-
Differences in Gene Expression Patterns, Revealed by RNA-Seq Analysis, Between Various Sanfilippo and Morquio Diseas...Mucopolysaccharidoses (MPS) are genetic ...
-
Raising an Adult Child With Sanfilippo Syndrome Is TiringI am tired. Caring for my 25-year-old da...
-
Music Therapy and Sanfilippo Syndrome: an Analysis of Psychological and Physiological Variables of Three Case Studie...Mucopolysaccharidosis type III (MPS III)...
-
A Multicenter Open-Label Extension Study of Intrathecal Heparan-N-Sulfatase in Patients With Sanfilippo Syndrome Typ...Sanfilippo syndrome type A (mucopolysacc...
-
Sanfilippo Children’s Foundation – FacebookSanfilippo Children's Foundation is a no...
-
Intracerebral Gene Therapy in Four Children With Sanfilippo B Syndrome: 5.5-Year Follow-Up ResultsWe report the safety (primary endpoint) ...
Powered by
